A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2-positive early breast cancer.

Park, I. H.; Lee, K. S.; Kang, Hyejin; Kwon, Yong-hwan; Kim, S. W.; Lee, S.; Jung, Su Yon; Shin, K.H.; Ko, Kyung Rae; Nam, B-H; Ro, Jungsil

doi:10.1200/jco.2011.29.15_suppl.e11069

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overexpression of NAMPT is associated with aggressive pathological and molecular features, such as estrogen receptor negativity and HER2-enriched phenotypes (26), as well as malignancy and poor prognosis (27,28). VEGF, an angiogenic marker, is found to be overexpressed in primary breast cancer (29) and plays a role in breast cancer angiogenesis (30), whereas HER2 positivity and negativity are related to the therapy of breast cancer (31,32). Previous study also showed that the overexpression of HER2 was significantly correlated to a higher expression of VEGF in breast cancer (21), but the clinical association of NAMPT/VEGF/HER2 with breast cancer has not been previously reported.…”

Section: Clinicopathological ----------------------------------------mentioning

confidence: 99%

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

et al. 2015

View full text Add to dashboard Cite

The early detection of breast cancer, the most common malignant tumor disease in women worldwide, relies on mammography and self breast examination. Here we evaluated the concentration of nicotinamide phosphoribosyltransferase (NAMPT), vascular endothelial growth factor (VEGF) and human epidermal growth factor receptor-2 (HER2) in serum and their expression in breast tissues associated with the clinicopathological features of patients with benign and malignant breast tumors. The immunohistochemical analysis showed that NAMPT, VEGF and HER2 proteins were overexpressed in breast tumors. The highest expression was observed in malignant tumors, low in benign tumors and negative in the adjacent normal tissue, indicating that the triplets may be progression markers and correlated with each other. The detection rate of NAMPT, VEGF and HER2 alone in tissue was 54.17, 64.58 and 60.42%, respectively, and was increased to about 79% in double combination and to 90% in triple combination. The basal levels of serum NAMPT, VEGF and HER2 in healthy controls were 94.90±4.24 pg/ml, 87.02±2.41 pg/ml and 1.12±0.04 ng/ml, respectively, measured by ELISA and found to be increased by 6.64-, 1.76- and 2.52-fold, respectively, in patients with malignant breast tumor. These elevated serum levels of NAMPT, VEGF and HER2 in patients were decreased after tumor removal, suggesting that these molecules are the indicators of treatment efficacy. The combined measurement of these triplets together may improve the sensitivity of breast cancer diagnosis and may potentially be used as a testing panel for the detection of malignant tumors, the assessment of treatment effectiveness and the monitoring of the disease progression in patients with breast cancer. Thus, we propose that the biomarker triplet NAMPT/VEGF/HER2 can be used as a de novo detection panel for the diagnosis and prognosis of human breast cancer.

show abstract

Section: Clinicopathological ----------------------------------------mentioning

confidence: 99%

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This regimen was well tolerated so there are now plans for a Phase 2. 39 Another Phase 1 study of Lapatinib plus Docetaxel, Carboplatin and T rastuzumab (TCarboH) in the adjuvant setting required Lapatinib dose reductions to 750 mg/day due to diarrhea, highlighting the fact that in chemotherapy combinations with lapatinib, diarrhea may be a dose limiting toxicity. 40 …”

Section: Lapatinib and Other 2 Or 3 Drug Combinationsmentioning

confidence: 99%

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer

Rana

Sridhar

2012

Breast Cancer�(Auckl)

View full text Add to dashboard Cite

Approximately 20%–25% of all breast cancers over express a key cell surface growth factor receptor known as HER2. HER2 plays a key role in cell growth and proliferation and is linked to worse clinical outcomes, making it a logical therapeutic target. The first HER2 targeted drug to be approved by the FDA, was the humanized monoclonal antibody trastuzumab, after it showed improvements in survival in the adjuvant setting, and delayed time to progression in the metastatic setting. Although highly effective, for reasons that are not clear, some patients display resistance to trastuzumab. Lapatinib is an oral, small molecule tyrosine kinase inhibitor, that inhibits both the HER1 ahd HER2 receptors and may be able to overcome trastuzumab resistance. Lapatinib is approved in the second line setting for use in combination with capecitabine or with letrozole. In this review, we will discuss the indications, concerns or any issues with regards to the drug.

show abstract

A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2-positive early breast cancer.

Cited by 2 publications

References 0 publications

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer

Contact Info

Product

Resources

About